Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
In the long term, the TBM programme aims at contributing to the implementation of (new) therapies, diagnostic techniques and preventive methods, which, without this government funding, would not make it to the patient due to a lack of industrial interest.
A TBM project meets the following criteria:
1. It is aimed at advancing a new therapy, diagnosis and/or specific prevention of a particular human disease/medical issue or comparing existing therapies, diagnostics or preventive methods in order to find out their relative efficacy and cost-effectiveness.
2. It is directed at research that is positioned late in the path from discovery to a specific application (i.e. there is a clinically relevant proof of concept) and aims at translating scientific findings into clinical applications rather than creating new knowledge from scratch. On the other hand, it is not positioned too late in the path from discovery to application: it does not consist of implementation activities that no longer require any research.
3. It offers a clear applicability with an added value for the Flemish health situation, including at least a positive medical impact for a particular group of patients or a cost reduction for the Flemish healthcare system.
4. At the time of submitting the application (or in the near future), the industry is not interested in the TBM project for commercial reasons.
New: The application form now includes an additional question regarding the substantive and/or conceptual contribution of the applicant(s) and any others to the research design, data collection, and the analysis or interpretation thereof. This information helps evaluators to better understand how the research proposal was developed and who contributed in which capacity. In this way, appropriate recognition is given to everyone involved in the proposal, regardless of their role. This section is solely for clarification and is not used as an additional assessment criterion.
Features
staffing, operation, equipment, subcontracting contracts (in accordance with cost model rules)
min. 215 000 EUR (excl. overhead) - max. 850 000 EUR (excl. overhead) (for large or multicentric trials, exceptionally budgets up to 1 275 000 EUR are allowed)
The results will be announced 26 November 2026. Projects start on 1 January 2027.
Pre-submission: All researchers who wish to propose a new project idea are strongly advised to send a presubmission inquiry whether the proposal matches the strict eligibility criteria in the form of a short abstract (see template) via e-mail to tbm@fwo.be. It is possible to request an oral preliminary discussion at FWO. If desired, written feedback can also be given. In addition, some host institutions will organise information sessions and meetings in collaboration with the FWO. For more information, please contact the responsible department of your host institution. The presubmission inquiry must reach the FWO at the latest one week before the submission deadline.
Internal submission deadline: The supervisor of the project submits the proposal via the FWO E-loket to the host institution (= main applicant of the proposal) by 13 April 2026 (5 PM).
Submission deadline: The host institution submits the proposal to FWO via the e-portal by 23 April 2026 (5 PM).
Evaluation procedure: The evaluation is performed by permanent panels consisting of scientific evaluators with diverse expertise in the biomedical sector and extensive experience in clinical trials. In addition, external (written) evaluators with expertise in the specific discipline of the project proposal are called upon.
Rebuttal: The interview has been replaced by a written rebuttal from 10-121 September 2026.
More information (slides info session, call related documents, handbook and templates for the submission) can be found on the FWO website.
13.04.2026, 23.04.2026
E-mail sarah.szyr@uhasselt.be
Tel. +3211269052